Valeant Pharmaceuticals International Inc (VRX.TO)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2016||Chairman of the Board, Chief Executive Officer|
|61||2016||Chief Financial Officer, Executive Vice President|
|52||2016||Executive Vice President, General Counsel|
|55||2016||Executive Vice President, Company Group Chairman, International|
|50||2017||Executive Vice President, Company Group Chairman, Dermatology|
- CANADA STOCKS-TSX in broad retreat led by Cenovus, other energy stocks
- CANADA STOCKS-TSX inches up, helped by railway stocks, gold miners weigh
- CANADA STOCKS-TSX advances, lifted by Valeant, financial services
- Drug industry group sues to stop California drug price law
- CANADA STOCKS-TSX posts 2-week high as industrials lead broad-based rally